AstraZeneca (AZNCF) Stock Price, News & Analysis

Company Overview

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms. AstraZeneca is headquartered in Cambridge, England, and operates major research centers in the United Kingdom, the United States, Sweden and China. Its commercial organization spans more than 100 countries across North and South America, Europe, Asia Pacific, the Middle East and Africa, enabling broad access to its medicines.

Under the leadership of Chief Executive Officer Pascal Soriot since 2012, AstraZeneca has pursued a strategy of innovation and external collaboration. The company has established numerous strategic alliances with academic institutions, biotechnology firms and governmental agencies to accelerate the development of new therapies. Its investments in biopharmaceutical research have yielded several breakthrough approvals in recent years, reinforcing its position in key markets and therapeutic areas.

Key Stats

• Today's Range: $156.82 to $156.82
• 50-Day Range: $139.70 to $164.50
• 52-Week Range: $120.64 to $164.82
• Volume: 706 shs
• Average Volume: 2,861 shs
• Market Capitalization: N/A
• P/E Ratio: 192.18
• Dividend Yield: 1.79%
• Price Target: N/A
• Consensus Rating: N/A

AstraZeneca Stock Analysis - MarketRank™

AstraZeneca scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for AstraZeneca.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of AstraZeneca is 192.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 297.56.

Price to Earnings Ratio vs. Sector

The P/E ratio of AstraZeneca is 192.18, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 348.89.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

AstraZeneca has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.

Change versus previous month

Short interest in AstraZeneca has recently increased by 4.75%, indicating that investor sentiment is decreasing.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

AstraZeneca is a leading dividend payer. It pays a dividend yield of 3.89%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

AstraZeneca does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of AstraZeneca is 343.14%. Payout ratios above 75% are not desirable because they may not be sustainable.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

AstraZeneca has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.

Change versus previous month

Short interest in AstraZeneca has recently increased by 4.75%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.04

News Sentiment

AstraZeneca has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for AstraZeneca this week, compared to 6 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AstraZeneca insiders have not sold or bought any company stock.

Percentage Held by Institutions

40.87% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AZNCF Stock Analysis - Frequently Asked Questions

How have AZNCF shares performed this year?

AstraZeneca's stock was trading at $130.00 at the start of the year. Since then, AZNCF stock has increased by 20.6% and is now trading at $156.82.

Who are AstraZeneca's major shareholders?

AstraZeneca's top institutional shareholders include Boston Common Asset Management LLC.

How do I buy shares of AstraZeneca?

Shares of AZNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/22/2025
• Next Earnings (Estimated): 11/06/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:AZNCF
• CIK: 901832
• Web: www.astrazeneca.com
• Phone: 442037495000
• Fax: N/A
• Employees: 83,500
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 192.18
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A